Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

86.57 +4.97 (+6.09%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

December 19, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

December 08, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

December 01, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

November 25, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®

November 07, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

November 04, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

November 03, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

October 28, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

September 08, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

August 27, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

August 06, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

July 30, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

May 19, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

May 14, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 09, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL

May 09, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 07, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

April 30, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

April 28, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

April 14, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

LIVMARLI Now Approved in Japan for ALGS and PFIC

March 27, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.